c
Accretion Pharmaceuticals IPO is a bookbuilding of ₹29.75 crores. The issue is entirely a fresh issue of 29.46 lakh shares.
Accretion Pharmaceuticals IPO opens for subscription on May 14, 2025 and closes on May 16, 2025. The allotment for the Accretion Pharmaceuticals IPO is expected to be finalized on Monday, May 19, 2025. Accretion Pharmaceuticals IPO will be list on NSE SME with a tentative listing date fixed as Wednesday, May 21, 2025.
Accretion Pharmaceuticals IPO price band is set at ₹96 to ₹101 per share. The minimum lot size for an application is 1200. The minimum amount of investment required by retail investors is ₹1,15,200. But it is suggested to the investor to bid at the cutoff price to avoid the oversubscription senerio, which is about to ₹1,21,200. The minimum lot size investment for HNI is 2 lots (2,400 shares) amounting to ₹2,42,400.
Jawa Capital Services Private Limited is the book-running lead manager of the Accretion Pharmaceuticals IPO, while Kfin Technologies Limited is the registrar for the issue.The market maker for Accretion Pharmaceuticals IPO is Gretex Share Broking Private Limited.
Refer to Accretion Pharmaceuticals IPO RHP for detailed information.
Accretion Pharmaceuticals IPO Details
| IPO Date | May 14, 2025 to May 16, 2025 |
| Listing Date | [.] |
| Face Value | ₹10 per share |
| Issue Price Band | ₹96 to ₹101 per share |
| Lot Size | 1,200 Shares |
| Total Issue Size | 29,46,000 shares (aggregating up to ₹29.75 Cr) |
| Fresh Issue | 29,46,000 shares (aggregating up to ₹29.75 Cr) |
| Issue Type | Bookbuilding IPO |
| Listing At | NSE SME |
| Share Holding Pre Issue | 81,70,000 shares |
| Share Holding Post Issue | 1,11,16,000 shares |
| Market Maker Portion | 1,47,600 shares Gretex Share Broking Private Limited |
Accretion Pharmaceuticals IPO Reservation
| Investor Category | Shares Offered |
|---|---|
| QIB Shares Offered | Not more than 50.00% of the Net Issue |
| Retail Shares Offered | Not less than 35.00% of the Net Issue |
| NII (HNI) Shares Offered | Not more than 15.00% of the Net Issue |
Accretion Pharmaceuticals IPO Timeline (Tentative Schedule)
Accretion Pharmaceuticals IPO opens on May 14, 2025, and closes on May 16, 2025.
| IPO Open Date | Wed, May 14, 2025 |
| IPO Close Date | Fri, May 16, 2025 |
| Tentative Allotment | Mon, May 19, 2025 |
| Initiation of Refunds | Tue, May 20, 2025 |
| Credit of Shares to Demat | Tue, May 20, 2025 |
| Tentative Listing Date | Wed, May 21, 2025 |
| Cut-off time for UPI mandate confirmation | 5 PM on May 16, 2025 |
Accretion Pharmaceuticals IPO Lot Size
Investors can bid for a minimum of 1200 shares and in multiples thereof. The following table depicts the minimum and maximum investment by Retail Investors and HNI in terms of shares and amount.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 1200 | ₹1,21,200 |
| Retail (Max) | 1 | 1200 | ₹1,21,200 |
| HNI (Min) | 2 | 2,400 | ₹2,42,400 |
| Lot Size Calculator | |||
Accretion Pharmaceuticals IPO Promoter Holding
The promoters of the company are Mr. Mayur Popatlal Sojitra, Mr. Harshad Nanubhai Rathod, Mr. Vivek Ashok Kumar Patel and Mr. Hardik Mukundbhai Prajapati.
| Share Holding Pre Issue | 100.00% |
| Share Holding Post Issue | 73.48% |
About Accretion Pharmaceuticals Limited
Incorporated in 2012, Accretion Pharmaceuticals Limited is a pharmaceutical company that manufactures and sells tablets, capsules, and other healthcare products.
The company also offers contract manufacturing services. The Company manufactures and markets Tablets, Capsules, Oral Liquids, External Preparations (Ointment, Cream, Gel, Lotion, Medicated Shampoo, Mouthwash, Dusting Powder), and Oral Powder (Sachet, Dry Syrup).
The company also holds ISO 9001:2015, ISO 14001:2015, and ISO 22000:2005 certifications, reflecting its dedication to quality and environmental management systems.
The company's manufacturing unit is located in Ahmedabad, Sanand, Gujarat.
The company has expanded its global footprint, marking its presence in more than 20 countries, including regions in Africa, Southeast Asia, and the Middle East.
Product Portfolio and Services
- Tablets and Capsules – Covering antibiotics, anti-inflammatory, pain management, cardiovascular, and gastrointestinal medicines.
- Oral Liquids and Syrups – Used for respiratory, pediatric, and digestive treatments.
- External Preparations – Including medicated lotions, gels, ointments, and dusting powders for skin care and dermatological treatments.
- Ayurvedic and Herbal Products – Focused on natural wellness solutions for immunity, digestion, and general health.
As of January 2025, the company has 83 employees (including 4 Executive Directors) on its payroll.
Competitive Strength:
- Experienced Promoters and Management Team.
- Long-standing relationship with clients and suppliers.
- Focus on providing quality products.
- Management has built a supply chain and customer relations, creating goodwill and trust.
- Read Less
Company Financials
Accretion Pharmaceuticals Limited Financial Information (Restated Consolidated)
| Period Ended | 31 Dec 2024 | 31 Mar 2024 | 31 Mar 2023 | 31 Mar 2022 |
| Assets | 39.99 | 27.05 | 20.58 | 17.74 |
| Revenue | 35.75 | 33.94 | 29.53 | 22.58 |
| Profit After Tax | 5.24 | 3.88 | 0.10 | 0.08 |
| Net Worth | 13.58 | 5.35 | 3.84 | 3.08 |
| Reserves and Surplus | 5.41 | 1.35 | 0.00 | 0.00 |
| Total Borrowing | 13.79 | 13.48 | 8.47 | 7.61 |
| Amount in ₹ Crore | ||||
Key Performance Indicator (KPI)
The market capitalization of Accretion Pharmaceuticals IPO is Rs 112.27 Cr.
KPI as of Sun, Mar 31, 2024.
| KPI | Values |
|---|---|
| ROE | 72.47% |
| ROCE | 36.73% |
| Debt/Equity | 2.52 |
| RoNW | 72.47% |
| PAT Margin | 11.51 |
| Price to Book Value | 7.55 |
Check Accretion Pharmaceuticals IPO Peer Comparison here.
| Pre IPO | Post IPO | |
|---|---|---|
| EPS (Rs) | 4.74 | 6.28 |
| P/E (x) | 21.29 | 16.08 |
Note:
- The Pre IPO EPS is calculated based on Pre issue shareholding as on date of RHP and the latest FY earnings as of March 31, 2024 that is available in RHP.
- The Post Issue EPS is calculated based on the Post issue shareholding and annualized FY earnings of December 31, 2024 that is available in RHP.
Objects of the Issue (Accretion Pharmaceuticals IPO Objectives)
The Company Accretion Pharmaceuticals IPO proposes to utilise the Net Proceeds from the Issue towards the following objects:
| S.No. | Objects of the Issue | Expected Amount (in Millions) |
|---|---|---|
| 1 | Capital expenditure towards purchase of new equipment/ machineries, etc. | 26.97 |
| 2 | Capital expenditure towards upgradation of existing manufacturing facility | 46.56 |
| 3 | Repayment/prepayme nt of certain borrowings availed by the Company | 9.92 |
| 4 | Funding working capital requirements | 146.80 |
| 5 | General Corporate Purpose |
Read more https://newipo.info/ipo-gmp/
Read more https://newipo.info/cryptocurrency/